The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1):

##STR00001##

wherein each of R.sup.1 and R.sup.2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R.sup.3a and R.sup.3b or R.sup.4a and R.sup.4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R.sup.5 (R.sup.5 represents, for example, a hydrogen atom or a C.sub.1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O).sub.l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.

An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1):

##STR00001##

wherein each of R.sup.1 and R.sup.2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R.sup.3a and R.sup.3b or R.sup.4a and R.sup.4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R.sup.5 (R.sup.5 represents, for example, a hydrogen atom or a C.sub.1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O).sub.l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.